Document Detail

Perinatal exposure to maternal lamotrigine: clinical considerations for the mother and child.
MedLine Citation:
PMID:  21075992     Owner:  NLM     Status:  MEDLINE    
QUESTION: The question of neonatal safety during breastfeeding when mothers are taking lamotrigine (LTG) has become more prevalent in my practice. There are some theoretical concerns about breastfeeding while taking LTG, which have been compounded by a published case report of toxicity in the breastfed neonate of a mother taking LTG. How should I advise my patients who wish to breastfeed while taking LTG?
ANSWER: Most neonates born to mothers taking LTG have already been exposed to the drug for 9 months in utero, given the chronic indications for which the drug is intended. Lamotrigine exposure via breast milk is considerably less than placental transfer, with serum LTG concentrations in neonates higher at birth than during lactation. While a single case of toxicity has been reported in a neonate exposed to LTG via breast milk, in most circumstances, breastfeeding can be initiated and maintained given the tremendous benefits of mothers' milk. On the other hand, toxicity during breastfeeding might occur more commonly in the mother, if sufficient and gradual dose readjustments are not undertaken in the weeks following delivery.
Parvaz Madadi; Shinya Ito
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Canadian family physician Médecin de famille canadien     Volume:  56     ISSN:  1715-5258     ISO Abbreviation:  Can Fam Physician     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-15     Completed Date:  2012-03-30     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  0120300     Medline TA:  Can Fam Physician     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  1132-4     Citation Subset:  IM    
Motherisk Team at Hospital for Sick Children in Toronto, Ont.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / adverse effects*,  pharmacokinetics
Breast Feeding*
Epilepsy / drug therapy
Infant, Newborn
Lactation / metabolism
Maternal Exposure / adverse effects*
Milk, Human / metabolism
Postpartum Period
Pregnancy Complications / drug therapy
Prenatal Exposure Delayed Effects
Risk Factors
Triazines / adverse effects*,  pharmacokinetics
Reg. No./Substance:
0/Anticonvulsants; 0/Triazines; U3H27498KS/lamotrigine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Approach to assessing fitness to drive in patients with cardiac and cognitive conditions.
Next Document:  Influenza vaccination for children with asthma.